{"analyses":[{"ciLowerLimit":"-52.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.26","estimateComment":"Absolute difference \\>0 represent better response achieved on pevonedistat combination compared to azacitidine treatment alone.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.296","pValueComment":"P-value is from an unstratified Cochran-Mantel-Haenszel chi-square test.","paramType":"Absolute Rate Difference","paramValue":"-18.82","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0"},{"groupId":"OG001","value":"41.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Disease response for low-blast AML is based on the revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0\\*10\\^9/L and plt of \\>=1.0\\*10\\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all of the criteria for CR except for residual neutropenia (\\<1.0\\*10\\^9/L) or thrombocytopenia (TTP) (\\<100\\*10\\^9/L). The percentages are rounded off to report the nearest whole numbers.","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"NUMBER","populationDescription":"REP included all participants who received at least 1 dose of study drug and had a Baseline and at least 1 postbaseline disease assessment. Overall number analyzed are the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"From date of randomization until CR (up to approximately 5 years)","title":"Percentage of Participants With CR in Low-blast AML","type":"SECONDARY","unitOfMeasure":"percentage of participants"}